Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Magnesium deficiency in the organism is one of the most common human deficiency states. The prevalence of magnesium deficiency is about 15%, and suboptimal magnesium level is observed more than in 30% of people in the general population. Clinical signs of hypomagnesaemia are observed in 40% of patients in general care hospitals, in 70% of patients - in intensive care units, and magnesium deficiency occurs in 90% of patients with acute coronary syndrome. Magnesium metabolic disorders in the organism accelerate significantly development of complications of coronary heart disease, hypertension, type 2 diabetes, asthma and a number of neurological and psychiatric diseases. The value of this macro in the body is well studied, and its daily need is identified depending on age and sex. It is known that magnesium intake with the food does not cover an organism need. It is a rationale for preventive and therapeutic use of magnesium based drugs in various diseases. Organic salts of magnesium are recommended for these purposes. Magnesium metabolic disorders, approaches to pharmacotherapeutic correction of magnesium deficiency, advantages of magnesium salts of orotic acid are reviewed.

About the Author

I. I. Esenova
I.M. Setchenov First Moscow State Medical University
Russian Federation


1. Gromova O.A, Gogoleva I.V. The use of magnesium in the mirror of evidence-based medicine and basic research into therapies. Farmateka 2007; 146(12):104-110. Russian (Громова О.А, Гоголева И.В. Применение магния в зеркале доказательной медицины и фундаментальных исследований в терапии. Фарматека 2007; 146(12):104-110).

2. Schlingmann K.P., Gudermann T. A critical role of TRPM channel-kinase for human magnesium transport. J Physiol 2005; 566 (Pt 2): 301–308.

3. Schimatschek H.F., Rempis R. Prevalence of hypomagnesaemia in an unselected German population of 16,000 individuals. Magnes Res 2001;14(4):283-90.

4. Gartside P.S., Glueck C.J. The important role of modifiable dietary and behavioral characteristics in the causation and prevention of coronary heart disease hospitalization and mortality: the prospective NHANES I follow-up study. J Am Coll Nutr 1995;14(1):71-9.

5. Gorodeckij V.V., Talibov O.B. Preparations of magnesium in clinical practice. Small encyclopedia of magnesium. Moscow: Medpraktika; 2006. Russian (Городецкий В.В., Талибов О.Б. Препараты магния в медицинской практике. Малая энциклопедия магния. М.: Медпрактика; 2006).

6. Nedogoda S.V. The role of magnesium products in the management of patients of therapeutic profile. Lechawij vrach 2009; 6: 61-66. Russian (Недогода С.В. Роль препаратов магния в ведении паци-ентов терапевтического профиля. Лечащий врач 2009; 6: 61-66).

7. Ezhov A.V., Pimenov L.T., Zamost'janov M.V. Clinical efficacy in the treatment of magnerota stable angina in combination with hypertension in the elderly. Rossijskie medicinskie vesti 2001; 1: 71–74. Russian (Ежов А.В., Пименов Л.Т., Замостьянов М.В. Клиническая эффективность магнерота в лечении стабильной стенокардии напряжения в сочетании с артериальной гипертензией у лиц пожилого возраста. Российские медицинские вести 2001; 1: 71–74).

8. Sidorenko, G.I. Magnesium salts and their importance in the pathogenesis and treatment of cardiovascular diseases. Medicinskie novosti 1997; 8: 3-8. Russian (Сидоренко, Г.И. Соли магния и их значение в патогенезе и лечении сердечно-сосудистых заболеваний. Медицинские новости 1997; 8: 3-8).

9. Spasov A.A. Magnesium in clinical practice. Volgograd: OOO "Otrok"; 2000. Russian (Спасов А.А. Магний в медицинской практике. Волгоград: ООО "Отрок"; 2000).

10. Rebrov V.G., Gromova O.A. Vitamins and minerals. Moscow: Alev-V; 2003. Russian (Ребров В.Г., Громова О.А. Витамины и микроэлементы. М: Алев-В; 2003).

11. Ershov Ju.A. Chemistry of nutrients.. Moscow: Vysshaja shkola; 2000. Russian (Ершов Ю.А. Химия биогенных элементов. М.: Высшая школа; 2000).

12. Ma B., Lawson A.B., Liese A.D., Bell R.A., Mayer-Davis E.J. Dairy, magnesium, and calcium intake in relation to insulin sensitivity: approaches to modeling a dose-dependent association. Am J Epidemiol 2006; 164(5): 449–458.

13. Liao F., Folsom A.R., Brancati F.L. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 1998; 136: (3): 480–490.

14. Kumari K.T., Augustine J., Leelamma S. et al. Elevated serum glycosaminoglycans with hypomagnesemia in patients with coronary artery disease & thrombotic stroke. Indian J Med Res 1995; 101: 115– 129.

15. Shilov A.M., Martynov A.I., Sviatov I.S. The influence of magnesium-containing agents on blood rheology and hemocoagulation in patients with heart ischemia. Klin Med (Mosk). 1999;77(10):39-41. Russian (Шилов А.Н, Мартынов А.И., Святов И.С. и др. Влияние препаратов магния на реологические свойства крови и систему гемокоагуляции у больных ИБС. Клин медицина 1999;10:39-41).

16. Horner S.M. Efficacy of intravenous magnesium in acute myocardial infarction in reducing arrhythmias and mortality. Meta-analysis of magnesium in acute myocardial infarction. Circulation 1992; 86: 774–779.

17. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345(8951):669-85.

18. Ueshima K. Magnesium and ischemic heart disease: a review of epidemiological, experimental, and clinical evidences. Magnes Res 2005; 18(4): 275–284.

19. Polderman K.H., Peerdeman SM, Girbes AR. Hypophosphatemia and hypomagnesemia induced by cooling in patients with severe head injury. J Neurosurg 2001; 94(5): 697–705.

20. Sontia B., Touyz R.M. Role of magnesium in hypertension. Arch Biochem Biophys 2007; 458(1): 33–39.

21. Tubek S. Role of trace elements in primary arterial hypertension: is mineral water style or prophylaxis? Biol Trace Elem Res 2006; 1–3: 1–6.

22. Wexler R., Aukerman G. Nonpharmacologic strategies for managing hypertension // American Family Physician 2006; 1: 73: 11.

23. Shechter M. Walnuts and endothelial function in hypercholesterolemic subjects. Circulation 2004; 110: 58.

24. Talibov, O.B., Gorodeckij V.V. Magnesium in cardiology practice. Terapevt 2006; 10: 46-55. Russian (Талибов, О.Б., Городецкий В.В. Магний в кардиологической практике. Терапевт 2006; 10: 46-55).

25. Ostroumova O.D., Sharkova N.E. Diselectrolyte disorders and cardiovascular diseases. Magnesium deficiency in the pathogenesis of hypertension — a new target for therapy? Russkij medicinskij zhurnal 2003;15:856-859. Russian (Остроумова О.Д., Шаркова Н.Е. Дизэлектролитные расстройства и сердечно-сосудистые заболевания. Дефицит магния в патогенезе артериальной гипертонии — новая мишень для терапии? Русский медицинский журнал 2003;15:856-859).

26. Itoh K., Kawasaka T., Nakamura M. The effects of high oral magnesium supplementation on blood pressure, serum lipids and related variables in apparently healthy Japanese subjects. Lancet 1995;345(8951):669-85.

27. Ravn H.B., Korsholm T.L., Falk E. Oral magnesium supplementation induces favorable antiatherogenic changes in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2001;21(5):858-62.

28. Witte K.K., Nikitin N.P., Parker A.C. et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J 2005; 21: 2238–2244.

29. Bobkowski W., Nowak A., Durlach J. The importance of magnesium status in the pathophysiology of mitral valve prolapsed. Magnes Res 2005; 1: 35–52.

30. Lima Mde L., Pousada J., Barbosa C., Cruz T. Magnesium deficiency and insulin resistance in patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metabol 2005; 6: 959–963.

31. Lopez-Ridaura R., Willett W.C., Rimm E.B., et al. Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care 2004; 27: 134–140.

32. Rumawas M.E., McKeown N.M., Rogers G. et al. Magnesium intake is related to improved insulin home-ostasis in the framingham offspring cohort. J Am Coll Nutr 2006;25(6):486-92.

33. Trachtenbarg D.E. Diabetic Ketoacidosis. Am Fam Physician 2005;71(9):1705-14.

34. He K., Liu K., Daviglus M.L. et al. Magnesium Intake and Incidence of Metabolic Syndrome Among Young Adults. Circulation 2006; 113: 1675–1682.

35. Costello J., Howes M. Best evidence topic report. Nebulised magnesium in asthma. Emerg Med J 2004;21(5):586-7.

36. González J.A., Garcia C.H., González P.A. et al. Effect of Intravenous Magnesium Sulfate on Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization: A Randomized Placebo-Controlled Trial. Arch Bronconeumol 2006;42(8):384-7.

37. Massey L. Magnesium therapy for nephrolithiasis. Magnes Res 2005; 2: 123–126.

38. Tucker K.L., Hannan M.T., Chen H. et al. Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women. Am J Clin Nutr 1999; 69: 727–736.

39. Kanofsky J.D., Sandyk R. Magnesium deficiency in chronic schizophrenia. Int J Neurosci 1991;61(1-2):87-90.

40. Gupta S.K., Manhas A.S., Gupta V.K., Bhatt R. Serum magnesium levels in idiopathic epilepsy. J Assoc Physicians India 1994;42(6):456-7.

For citation:

Esenova I.I. FOCUS ON MAGNESIUM BASED DRUGS. Rational Pharmacotherapy in Cardiology. 2011;7(4):487-491. (In Russ.)

Views: 299

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)